X4 Pharmaceuticals Inc（XFOR）資訊與事件

$4.040

-0.181 (-4.49%)收盤時

XFOR 資訊

9.508-06seekingalpha

X4 Pharmaceuticals Q2 Earnings Beat Expectations

8.508-06Globenewswire

X4 Pharmaceuticals Strengthens Clinical Operations, Secures EU Approval for XOLREMDI®

5.008-03Globenewswire

X4 Pharmaceuticals Grants Stock Options to New Employees

5.008-03Newsfilter

X4 Pharmaceuticals Grants Stock Options to New Employees

6.007-10CNBC

Wall Street's Latest Ratings Overview

5.007-07Newsfilter

X4 Pharmaceuticals Grants Inducement Awards to New Employees

5.007-01Newsfilter

X4 Pharmaceuticals Appoints Kelly Gold to Board of Directors

9.505-07seekingalpha

X4 Pharmaceuticals Q1 Earnings Beat Expectations

8.505-06Newsfilter

X4 Pharmaceuticals Completes EU Approval for XOLREMDI®

5.004-01Newsfilter

X4 Pharmaceuticals Grants Inducement Awards to New Employees

查看更多資訊

XFOR 事件

8/26 09:00

X4 Pharmaceuticals' Mavorixafor Granted FDA Orphan Designation

X4 Pharmaceuticals' mavorixafor was granted FDA orphan designation as a treatment of congenital neutropenia, according to a post to the agency's website.

8/6 18:00

X4 Pharmaceuticals Reports Q2 Revenue of $8.81M

Reports Q2 revenue $8.81M, consensus $2.42M. "Since we began leading X4 last August, we have taken meaningful actions to strengthen the execution of the mavorixafor Phase 3 4WARD trial in chronic neutropenia, positioning 4WARD for the successful completion of enrollment," said Adam Craig, Executive Chairman of X4 Pharmaceuticals. "Following our complete overhaul of the clinical operating infrastructure and engagement of a top oncology Clinical Research Organization to manage the Phase 3 trial, we are now in a position to revisit the sample size of the study with the FDA. We expect to provide an update on our meeting with the FDA and the completion of enrollment by the end of the third quarter."

7/1 07:30

X4 Pharmaceuticals Appoints Kelly Gold as Independent Director

X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company's board of directors effective July 1, adding strong strategic and financial expertise. Gold will serve as an independent director and member of the audit committee. Gold is currently the CFO at CAMP4 Therapeutics (CAMP).

5/6 16:20

X4 Pharmaceuticals Files $300M Mixed Securities Shelf

X4 Pharmaceuticals files $300M mixed securities shelf

5/6 08:10

X4 Pharmaceuticals Q1 Revenue $2.71M, Below Consensus

Reports Q1 revenue $2.71M, consensus $3.2M. "Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia," said Adam Craig, Executive Chairman of X4 Pharmaceuticals. "We remain on track to complete enrollment by the end of the third quarter of this year. In addition, we are pleased that the European Commission granted marketing authorization for XOLREMDI for the treatment of patients with WHIM syndrome in the European Union, reinforcing the broader potential of our program to advance therapies for individuals affected by rare hematologic disorders. We look forward to a smooth transfer of the marketing authorization application to our European partner, Norgine, later this year as they proceed with commercialization plans throughout Europe."

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。